Add time:07/25/2019         Source:sciencedirect.com

Synthetic cannabinoid abuse and case reports of adverse effects have raised concerns about the pharmacologic mechanisms underlying in vivo effects. Here, a synthetic cannabinoid identified in abused products (HU-210) was compared to the effects of Δ9-THC and two other synthetic cannabinoid agonists used extensively in pre-clinical studies (CP 55,940 and WIN 55,212-2). One group of monkeys discriminated ∆9-THC (0.1 mg/kg i.v.); a separate group received chronic ∆9-THC (1 mg/kg/12 h s.c.) and discriminated rimonabant (1 mg/kg i.v.). CP 55,940, HU-210, ∆9-THC, and WIN 55,212-2 produced ∆9-THC lever responding. HU-210 had a long duration (i.e., 1–2 days), whereas that of the other cannabinoids was 5 h or less. Rimonabant (1 mg/kg) produced surmountable antagonism; single dose-apparent affinity estimates determined in the presence of ∆9-THC, CP 55,940, and WIN 55,212-2 did not differ from each other. In contrast, rimonabant (1 mg/kg) produced a smaller rightward shift in the HU-210 dose–effect function. In ∆9-THC treated monkeys, the relative potency of CP 55,940, ∆9-THC, and WIN 55,212-2 to attenuate the discriminative stimulus effects of rimonabant was the same as that evidenced in the ∆9-THC discrimination, whereas HU-210 was unexpectedly more potent in attenuating the effects of rimonabant. In conclusion, the same receptor subtype mediates the discriminative stimulus effects of ∆9-THC, CP 55,940 and WIN 55,212-2. The limited effectiveness of rimonabant to either prevent or reverse the effects of HU-210 appears to be due to very slow dissociation or pseudo-irreversible binding of HU-210 at cannabinoid receptors.

We also recommend Trading Suppliers and Manufacturers of HU-210 (cas 112830-95-2). Pls Click Website Link as below: cas 112830-95-2 suppliers